Pharma channel feed – Endpoints News

Pharma channel feed

As NDA talks loom, FDA hands Daiichi Sankyo a ‘breakthrough’ on its $410M AML drug quizartinib

7 years ago

FDA hustles through a quick OK for Shionogi's new thrombocytopenia drug

7 years ago

FDA approves cancer radiation drug Azedra, sending Progenics stock north

7 years ago

We've scheduled your Type T meeting with FDA commish Scott Gottlieb, where you can learn the art of rapid fire R&D

7 years ago

As it fights looming competition on Suboxone, Indivior gets FDA OK on new schizophrenia drug

7 years ago

FDA outlines a laundry list of surrogate endpoints with an eye to expanding the roster for drug developers

7 years ago

Kickback, bribery and racketeering charges are followed by a CRL for opioid spray at scandal-plagued Insys

7 years ago

FDA finalizes guidance closing pediatric study loophole

7 years ago

After an epic battle of blockbusters, Merck leapfrogs Bristol-Myers to take the lead on PD-1/L1 market

7 years ago

Bristol-Myers takes another hit on Opdivo/Yervoy combo as CHMP turns thumbs down on frontline kidney cancer

7 years ago

On top of expiring Herceptin patents, Roche faces huge royalty losses in 2019

7 years ago

Looking to mount an R&D turnaround, GSK gets slapped down at the FDA for a weak stab at COPD

7 years ago

Acorda shares tank as appeals court refuses injunction against cheap Ampyra knockoffs

7 years ago

Zavante CEO sells his late-stage antibiotic biotech to Nabriva — grabbing the helm in the deal

7 years ago

Biogen climbs higher on Spinraza sales; inks deal for two new neuromuscular drugs

7 years ago

Following some clean sweeps in PhIII, AbbVie gets an FDA OK on its top-10 blockbuster prospect Orilissa

7 years ago

As Eisai, Biogen plot a course to accelerated approvals for Alzheimer’s drug, a mob of skeptics are waiting to decipher hard numbers

7 years ago

GSK gains a PRV alongside FDA approval for recurring malaria treatment

7 years ago

FDA poses some tough questions for GSK’s pitch to gain an approval for Nucala in COPD

7 years ago

Lilly inks R&D deal with Anima, paying $44M in research funding and upfront payments

7 years ago

Agios scores its second new drug approval, ivosidenib heads to the AML market

7 years ago

Sobi signs $450M deal for rare disease drug emapalumab, boosting its inflammation, I/O pipeline

7 years ago

Roche has taken the Trump pledge, joining Pfizer, Novartis and Merck in promising to hold the line on drug prices

7 years ago

PureTech grabs up to $36M from Roche to research milk-inspired delivery platform

7 years ago

First page Previous page 292 293 294295296 297 298 Next page Last page